Product
ISB 1442
1 clinical trial
1 indication
Indication
Multiple MyelomaClinical trial
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2027-05-01